Allogene Therapeutics (ALLO) Current Assets (2019 - 2025)
Historic Current Assets for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $260.7 million.
- Allogene Therapeutics' Current Assets fell 1435.41% to $260.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $260.7 million, marking a year-over-year decrease of 1435.41%. This contributed to the annual value of $303.4 million for FY2024, which is 3391.94% down from last year.
- Per Allogene Therapeutics' latest filing, its Current Assets stood at $260.7 million for Q3 2025, which was down 1435.41% from $282.7 million recorded in Q2 2025.
- Over the past 5 years, Allogene Therapeutics' Current Assets peaked at $716.1 million during Q1 2021, and registered a low of $260.7 million during Q3 2025.
- Its 5-year average for Current Assets is $451.8 million, with a median of $471.3 million in 2021.
- Within the past 5 years, the most significant YoY rise in Allogene Therapeutics' Current Assets was 4195.9% (2021), while the steepest drop was 4423.07% (2021).
- Quarter analysis of 5 years shows Allogene Therapeutics' Current Assets stood at $471.3 million in 2021, then increased by 12.2% to $528.8 million in 2022, then decreased by 13.18% to $459.1 million in 2023, then plummeted by 33.92% to $303.4 million in 2024, then decreased by 14.06% to $260.7 million in 2025.
- Its Current Assets stands at $260.7 million for Q3 2025, versus $282.7 million for Q2 2025 and $291.6 million for Q1 2025.